Financhill
Sell
42

OCGN Quote, Financials, Valuation and Earnings

Last price:
$0.52
Seasonality move :
-3.76%
Day range:
$0.52 - $0.57
52-week range:
$0.52 - $2.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
34.50x
P/B ratio:
5.09x
Volume:
6.7M
Avg. volume:
3.8M
1-year change:
-49.87%
Market cap:
$150.8M
Revenue:
$4.1M
EPS (TTM):
-$0.19

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCGN
Ocugen
$300K -$0.05 -100% -- $6.75
ADMA
ADMA Biologics
$112.8M $0.15 41.07% 75% $25.27
EDIT
Editas Medicine
$37.2M -$0.33 -23.05% -22.53% $3.75
EYPT
EyePoint Pharmaceuticals
$11M -$0.48 -24.38% -22.59% $33.00
INSM
Insmed
$102.4M -$1.16 19.4% -27.03% $95.54
TGTX
TG Therapeutics
$100.7M $0.20 84.44% -95.36% $42.83
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCGN
Ocugen
$0.52 $6.75 $150.8M -- $0.00 0% 34.50x
ADMA
ADMA Biologics
$18.71 $25.27 $4.4B 22.82x $0.00 0% 10.63x
EDIT
Editas Medicine
$1.32 $3.75 $109.1M -- $0.00 0% 3.35x
EYPT
EyePoint Pharmaceuticals
$6.21 $33.00 $426.8M -- $0.00 0% 8.08x
INSM
Insmed
$76.99 $95.54 $13.9B -- $0.00 0% 34.72x
TGTX
TG Therapeutics
$39.88 $42.83 $6.3B 284.86x $0.00 0% 18.99x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCGN
Ocugen
49.18% 4.395 12.22% 2.71x
ADMA
ADMA Biologics
17.17% 4.789 1.78% 2.76x
EDIT
Editas Medicine
-- 0.335 -- 3.71x
EYPT
EyePoint Pharmaceuticals
-- -2.597 -- 7.57x
INSM
Insmed
79.45% 6.110 8.91% 4.99x
TGTX
TG Therapeutics
52.36% 3.612 5.21% 4.85x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCGN
Ocugen
-- -$13.8M -136.46% -171.04% -1811.52% -$10.4M
ADMA
ADMA Biologics
$63.3M $38.3M 60.85% 93.41% 31.98% $23.9M
EDIT
Editas Medicine
-- -$34.4M -100% -100% -112.28% -$51.3M
EYPT
EyePoint Pharmaceuticals
$10.8M -$45.2M -50.34% -50.34% -356.36% -$36.2M
INSM
Insmed
$78.3M -$245.2M -82.19% -41989.34% -205.36% -$202.8M
TGTX
TG Therapeutics
$92.8M $29.9M 6.86% 12.81% 30.05% -$25.7M

Ocugen vs. Competitors

  • Which has Higher Returns OCGN or ADMA?

    ADMA Biologics has a net margin of -1816.75% compared to Ocugen's net margin of 95.19%. Ocugen's return on equity of -171.04% beat ADMA Biologics's return on equity of 93.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    ADMA
    ADMA Biologics
    53.88% $0.46 $421.4M
  • What do Analysts Say About OCGN or ADMA?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1207.38%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 35.08%. Given that Ocugen has higher upside potential than ADMA Biologics, analysts believe Ocugen is more attractive than ADMA Biologics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    ADMA
    ADMA Biologics
    4 0 0
  • Is OCGN or ADMA More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.

  • Which is a Better Dividend Stock OCGN or ADMA?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or ADMA?

    Ocugen quarterly revenues are $764K, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Ocugen's net income of -$13.9M is lower than ADMA Biologics's net income of $111.9M. Notably, Ocugen's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 22.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 34.50x versus 10.63x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    34.50x -- $764K -$13.9M
    ADMA
    ADMA Biologics
    10.63x 22.82x $117.5M $111.9M
  • Which has Higher Returns OCGN or EDIT?

    Editas Medicine has a net margin of -1816.75% compared to Ocugen's net margin of -148.33%. Ocugen's return on equity of -171.04% beat Editas Medicine's return on equity of -100%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    EDIT
    Editas Medicine
    -- -$0.55 $134.3M
  • What do Analysts Say About OCGN or EDIT?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1207.38%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 185.17%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    EDIT
    Editas Medicine
    4 9 0
  • Is OCGN or EDIT More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.

  • Which is a Better Dividend Stock OCGN or EDIT?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or EDIT?

    Ocugen quarterly revenues are $764K, which are smaller than Editas Medicine quarterly revenues of $30.6M. Ocugen's net income of -$13.9M is higher than Editas Medicine's net income of -$45.4M. Notably, Ocugen's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 34.50x versus 3.35x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    34.50x -- $764K -$13.9M
    EDIT
    Editas Medicine
    3.35x -- $30.6M -$45.4M
  • Which has Higher Returns OCGN or EYPT?

    EyePoint Pharmaceuticals has a net margin of -1816.75% compared to Ocugen's net margin of -357.26%. Ocugen's return on equity of -171.04% beat EyePoint Pharmaceuticals's return on equity of -50.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    EYPT
    EyePoint Pharmaceuticals
    92.96% -$0.64 $336.5M
  • What do Analysts Say About OCGN or EYPT?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1207.38%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 431.4%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    EYPT
    EyePoint Pharmaceuticals
    9 0 0
  • Is OCGN or EYPT More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.

  • Which is a Better Dividend Stock OCGN or EYPT?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or EYPT?

    Ocugen quarterly revenues are $764K, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocugen's net income of -$13.9M is higher than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocugen's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 34.50x versus 8.08x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    34.50x -- $764K -$13.9M
    EYPT
    EyePoint Pharmaceuticals
    8.08x -- $11.6M -$41.4M
  • Which has Higher Returns OCGN or INSM?

    Insmed has a net margin of -1816.75% compared to Ocugen's net margin of -225.53%. Ocugen's return on equity of -171.04% beat Insmed's return on equity of -41989.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    INSM
    Insmed
    74.96% -$1.32 $1.4B
  • What do Analysts Say About OCGN or INSM?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1207.38%. On the other hand Insmed has an analysts' consensus of $95.54 which suggests that it could grow by 24.1%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    INSM
    Insmed
    12 0 0
  • Is OCGN or INSM More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

  • Which is a Better Dividend Stock OCGN or INSM?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or INSM?

    Ocugen quarterly revenues are $764K, which are smaller than Insmed quarterly revenues of $104.4M. Ocugen's net income of -$13.9M is higher than Insmed's net income of -$235.5M. Notably, Ocugen's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 34.50x versus 34.72x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    34.50x -- $764K -$13.9M
    INSM
    Insmed
    34.72x -- $104.4M -$235.5M
  • Which has Higher Returns OCGN or TGTX?

    TG Therapeutics has a net margin of -1816.75% compared to Ocugen's net margin of 21.57%. Ocugen's return on equity of -171.04% beat TG Therapeutics's return on equity of 12.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCGN
    Ocugen
    -- -$0.05 $58.3M
    TGTX
    TG Therapeutics
    85.77% $0.15 $466.8M
  • What do Analysts Say About OCGN or TGTX?

    Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1207.38%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 7.41%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCGN
    Ocugen
    2 0 0
    TGTX
    TG Therapeutics
    5 0 0
  • Is OCGN or TGTX More Risky?

    Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.

  • Which is a Better Dividend Stock OCGN or TGTX?

    Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCGN or TGTX?

    Ocugen quarterly revenues are $764K, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocugen's net income of -$13.9M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocugen's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 284.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 34.50x versus 18.99x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCGN
    Ocugen
    34.50x -- $764K -$13.9M
    TGTX
    TG Therapeutics
    18.99x 284.86x $108.2M $23.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Pepsi Vs Coke Stock: Which Is Best?
Pepsi Vs Coke Stock: Which Is Best?

Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
52
RGC alert for Mar 19

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Sell
46
CVNA alert for Mar 19

Carvana [CVNA] is down 10.69% over the past day.

Buy
93
ESLT alert for Mar 19

Elbit Systems [ESLT] is up 10.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock